Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Puech

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Therapie|October 30, 2009
[Homage to Professor Pierre Simon]Alain Puech
Therapie|January 22, 2008
How to anticipate the assessment of the public health benefit of new medicines?Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Therapie|July 10, 2016
[Not Available]Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Therapie|January 22, 2008
[How should one anticipate the assessment of the public health benefit of new medicines?]Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Journal of Clinical Psychopharmacology|November 28, 2002
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophreniaMatthias J Müller, Hermann Wetzel, Franz-Xaver Eich, et al.
Plos One|March 12, 2016
The Combination of Marketed Antagonists of α1b-Adrenergic and 5-HT2A Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol DependenceFabrice Trovero, Sabrina David, Philippe Bernard, et al.
Therapie|January 22, 2008
[State of unmet medical needs in France in 2006: necessity of reinforcing research effort]Chrystel Jouan-Flahault, Nathalie Billon, Alain Castaigne, et al.
The Oncologist|October 31, 2014
A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancerNadine Houédé, Marina Pulido, Loic Mourey, et al.
Addiction (Abingdon, England)|April 10, 2024
Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trialHenri-Jean Aubin, Ivan Berlin, Julien Guiraud, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Therapie|October 30, 2009
[Homage to Professor Pierre Simon]Alain Puech
Therapie|January 22, 2008
How to anticipate the assessment of the public health benefit of new medicines?Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Therapie|July 10, 2016
[Not Available]Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Therapie|January 22, 2008
[How should one anticipate the assessment of the public health benefit of new medicines?]Jacques Massol, Alain Puech, Jean-Pierre Boissel, et al.
Journal of Clinical Psychopharmacology|November 28, 2002
Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophreniaMatthias J Müller, Hermann Wetzel, Franz-Xaver Eich, et al.
Plos One|March 12, 2016
The Combination of Marketed Antagonists of α1b-Adrenergic and 5-HT2A Receptors Inhibits Behavioral Sensitization and Preference to Alcohol in Mice: A Promising Approach for the Treatment of Alcohol DependenceFabrice Trovero, Sabrina David, Philippe Bernard, et al.
Therapie|January 22, 2008
[State of unmet medical needs in France in 2006: necessity of reinforcing research effort]Chrystel Jouan-Flahault, Nathalie Billon, Alain Castaigne, et al.
The Oncologist|October 31, 2014
A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancerNadine Houédé, Marina Pulido, Loic Mourey, et al.
Addiction (Abingdon, England)|April 10, 2024
Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trialHenri-Jean Aubin, Ivan Berlin, Julien Guiraud, et al.
Pageof 1